Morphic Holding Inc (MORF) Stock
MORF is no longer traded. Morphic Holding was acquired by Eli Lilly (LLY) in August 2024.
Each MORF share was exchanged for $57.00 in cash. Prices on this page are historical; the last trade was August 15, 2024 at $56.99.
See Eli Lilly (LLY) stock →Morphic Holding stock price history
MORF final trading statistics
- Final close
- $56.99
- Final trading day
- Aug 15, 2024
- Market cap at delisting
- $2.86B
- Shares outstanding
- 50.22M
- Final 52-week range
- $19.34 – $57.00
- Avg. volume (final 3 mo.)
- 2,443,553
- All-time high (split-adj.)
- $84.85 · Mar 2021
- All-time low (split-adj.)
- $10.84 · Mar 2020
- Return since IPO
- +216.6%
- Beta
- 1.49
- Book value / share
- $12.34
- Price / book
- 4.62
Morphic Holding annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $521.0K | -$152.1M | -$3.51 |
| FY2022 | $70.81M | -$59.0M | -$1.59 |
| FY2021 | $19.79M | -$94.2M | -$2.67 |
| FY2020 | $44.95M | -$45.0M | -$1.47 |
| FY2019 | $16.98M | -$43.3M | -$5.92 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Morphic Holding Inc
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Morphic Holding stock FAQ
What happened to Morphic Holding stock?
Morphic Holding was acquired by Eli Lilly (LLY) in August 2024. Shareholders received $57.00 in cash for each share. MORF stock stopped trading on the Nasdaq, with a final close of $56.99 on August 15, 2024.
What did Morphic Holding shareholders receive?
Each MORF share was converted into $57.00 in cash. The deal was valued at about $3.2 billion.
Is MORF stock still trading?
No. MORF was delisted from the Nasdaq in August 2024 and no longer trades on a U.S. exchange.
What was the last price of MORF stock?
MORF closed at $56.99 on its final trading day, August 15, 2024, for a market value of about $2.86B.
What were Morphic Holding's revenue and earnings in its last full fiscal year?
Morphic Holding reported revenue of $521.0K and net income of -$152.1M in fiscal 2023, its last full year as a public company.
When did Morphic Holding go public?
Morphic Holding Inc stock began trading on June 27, 2019.